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ABSTRACT
Background: Consumers of light-to-moderate amounts of alcohol
have a lower risk of dementia and, possibly, Alzheimer disease than
do abstainers. Because vascular disease may contribute to symptoms
of Alzheimer disease, reduction of cerebrovascular disease in con-
sumers of light amounts of alcohol could account for that observa-
tion. However, a low concentration of alcohol may also have direct
effects on the hippocampus, a brain structure highly affected by
Alzheimer disease.
Objective: We investigated alcohol intake in relation to brain mag-
netic resonance imaging (MRI) findings of presumed vascular origin
(ie, white matter lesions and infarcts) and findings more specifically
found in early Alzheimer disease (ie, hippocampal and amygdalar
atrophy).
Design: In a population-based sample of 1074 older persons without
dementia (aged 60–90 y), we made brain MRIs from which we rated
white matter lesions and brain infarcts. In a subset of 509 people,
hippocampal and amygdalar volumes on MRI were measured. Al-
cohol intake was assessed by using a structured questionnaire. We
categorized alcohol intake as lifetime abstention and very light (1
drink/wk), light (1 drink/wk to1 drink/d), moderate (1 drink/d
to4 drinks/d), and heavy (4 drinks/d) intakes.
Results: Persons whose alcohol consumption was light to moderate
had less severe white matter lesions and brain infarcts on MRI than
did abstainers or heavy drinkers. Abstainers and very light drinkers
had smaller hippocampal and amygdalar volumes on MRI than did
light-to-moderate drinkers, but only if the former carried an apoli-
poprotein (APOE) 4 allele.
Conclusion: Light-to-moderate alcohol intake is associated with a
lower prevalence of vascular brain findings and, in APOE 4 carri-
ers, hippocampal and amygdalar atrophy on MRI. Am J Clin
Nutr 2004;80:992–7.
KEY WORDS Alcohol, Alzheimer disease, brain, hippocam-
pus, amygdala, magnetic resonance imaging
INTRODUCTION
Several prospective, population-based studies have shown
that persons with light-to-moderate consumption of alcohol have
a lower risk of dementia than do persons who abstain or have
heavy alcohol use (1–4). Most studies find a relation with vas-
cular dementia (2, 4, 5) that is consistent with the known bene-
ficial effects of light-to-moderate alcohol consumption on vas-
cular risk profile (6) and risk of stroke (7). Vascular disease likely
contributes to the clinical syndrome in a large proportion of
elderly Alzheimer patients (8, 9). A plausible explanation for the
associations that are seen between alcohol consumption and
overall dementia or Alzheimer disease (3, 4, 10) is that they have
to do with an effect on vascular disease. Alternatively, alcohol in
low amounts could have stimulatory effects on the release of
acetylcholine in the hippocampus (11), and other nonvascular
mechanisms might play a role (12). A nonvascular relation be-
tween alcohol intake and Alzheimer disease was indeed sug-
gested by our observation in the Rotterdam Study that alcohol
intake seemed to be associated with Alzheimer disease only in
carriers of the apolipoprotein (APOE) 4 allele (2), which is the
risk allele for Alzheimer disease (13).
To further investigate what could underlie the relation be-
tween alcohol intake and risk of dementia, we decided to focus on
the relation between alcohol intake and structural brain findings
on magnetic resonance imaging (MRI) of older persons without
dementia. We hypothesized that, if the effect of alcohol on de-
mentia risk purely had to do with an effect on vascular disease, we
would see a relation between alcohol intake and markers of
cerebrovascular disease [eg, brain infarcts and white matter le-
sions (9, 14–16)], but not between alcohol intake and putative
presymptomatic MRI markers of Alzheimer disease [eg, hip-
pocampal and amygdalar atrophy (17–22)]. We investigated this
hypothesis in the population-based Rotterdam Scan Study.
SUBJECTS AND METHODS
Study sample
This study was based on data collected in the Rotterdam Scan
Study, a population-based cohort study designed to investigate
the determinants of age-related brain changes as seen on MRI and
their consequences (23). The study protocol has been described
in detail elsewhere (24). The study’s baseline examinations were
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conducted in1995 and 1996. At that time, we made a random
selection in strata of age (5 y) and sex of 1904 persons aged
60–90 y originating from 2 population cohort studies. We ex-
cluded from this sample persons with dementia, according to the
protocol of the Rotterdam Study (25) for detecting dementia.
Briefly, this stepwise protocol started with a cognitive screen
with the Mini-Mental State Examination and Geriatric Mental
Schedule organic part A. Persons who were positive on screening
underwent further neuropsychological testing and, if indicated,
were examined by a neurologist. After the exclusion of persons
with dementia or contraindications to MRI [eg, claustrophobia or
the presence of implanted metal clips (for cerebral aneurysms) or
a pacemaker], 1717 persons were eligible, of whom 1077 par-
ticipated and gave written informed consent (participation rate:
63%; mean age: 72.2 y; proportion of women: 52%). All 1077
persons underwent MRI sequences for assessment of white mat-
ter lesions and brain infarcts. In a subset of 563 of these 1077, the
MRI was done with the use of a unit (Siemens, Erlangen, Ger-
many) that allowed us to include a 3-dimensional (3-D) MRI
sequence needed for the assessment of hippocampal and amyg-
dalar volumes. The Medical Ethics Committee of Erasmus Med-
ical Center approved the study protocol.
Alcohol intake
A physician used a structured questionnaire to evaluate the
alcohol intake of each participant at baseline. Alcohol intake was
coded as lifetime abstention, former drinking, and current drink-
ing (defined as having consumed alcohol during the past 12 mo).
Current and former drinkers were asked about the amount of their
alcohol consumption. The amount assessed with this question-
naire correlated well with the information obtained from a food-
frequency questionnaire administered in part of the sample 5 y
earlier (Pearson’s r  0.72, P  0.01; 26). We categorized
current alcohol drinkers as very light (1 drink/wk), light (1
drink/wk to1 drink/d), moderate (1 drink/d to4 drinks/d),
and heavy (4 drinks/d) drinkers, as in our previous report on
dementia (2). One alcoholic drink (a glass of beer, wine, fortified
wine, or spirits) was considered to contain13 g alcohol. Binge
drinking was defined as drinking6 glasses in 1 d during the 6
mo before the interview. For 3 participants, information on al-
cohol intake was missing.
MRI acquisition
All 1077 participants underwent axial T1-, T2-, and proton
density–weighted brain MRI scanning with a 1.5-Tesla unit
(Philips, Best, Netherlands, or Siemens) at baseline (24). Only
the Siemens MRI unit, in which 563 participants had their MRI
scan, allowed us also to include a custom-made 3-D MRI se-
quence (half-Fourier Acquisition Single-Shot Turbo-Spin Echo;
27) needed for volumetric assessment of the hippocampus and
amygdala. Fifty-two of the 563 participants experienced claus-
trophobia during the MRI scan, and 2 others provided no infor-
mation on alcohol intake, which left 509 participants with infor-
mation on alcohol intake and hippocampal and amygdalar
volumes.
Cerebrovascular disease on MRI
MRI measurements were performed by investigators who
were blinded to clinical information of the participants (24, 28).
White matter lesions were considered present if visible as hy-
perintense on proton-density–and T2-weighted images, without
prominent hypointensity on T1-weighted scans. Periventricular
white matter lesions were scored semiquantitatively from 0 to 9,
and subcortical white matter lesions were counted in different
size categories to approximate a total lesion volume (in mL; 24).
We defined infarcts as focal hyperintensities on T2-weighted
images. Infarcts in the white matter also were required to have
corresponding hypointensities on T1-weighted images to distin-
guish them from white matter lesions. Infarcts on MRI were
classified as silent or symptomatic (28).
Hippocampal and amygdalar volumes on MRI
We constructed a series of coronal brain slices (contiguous
1.5-mm slice thickness) from the 3-D MRI, which were aligned
to be perpendicular to the long axis of the hippocampus. We
manually traced the boundaries of the hippocampus and amyg-
dala on both sides on each slice by using a mouse-driven cursor
(27). The summed surface areas were multiplied by slice thick-
ness to yield estimates of the hippocampal and amygdalar vol-
umes (mL). The left- and right-sided volumes were summed to
yield the total hippocampal and amygdalar volumes. As a proxy
for head size, we measured on the middle sagittal MRI slice the
intracranial cross-sectional area (27). We corrected for head size
differences among subjects by dividing the uncorrected volumes
by the subject’s calculated head size area and subsequently mul-
tiplying this ratio by the average head size area (separately for
men and women; 29, 30).
Covariates
The following covariates were assessed at baseline by inter-
view and physical examination: pack-years of cigarette smoking,
educational level, body mass index (BMI; in kg/m2), diabetes
mellitus, and hypertension (28). APOE genotype testing was
performed (31) and available for 969 participants in the total
sample and 436 participants in the subset with hippocampal and
amygdalar volume assessment; testing was not performed in the
rest of the subjects, mainly because no blood from them was
available. Participants were classified as carriers or noncarriers
of an APOE 4 allele; those with genotype APOE 24 (n 22
in the total sample and 9 in the subsample) were excluded from
analyses considering APOE genotype.
Statistical analysis
The analyses of alcohol intake and white matter lesions and
infarcts were based on 1074 persons, and the analyses of alcohol
intake and hippocampal and amygdalar volumes were based on
the subset of 509 persons. We used multivariable linear regres-
sion to quantify the association between alcohol-intake catego-
ries and white matter lesions and hippocampal and amygdalar
volumes. With logistic regression, we calculated the adjusted
odds ratio (95% CI) of brain infarcts across alcohol-intake cat-
egories by using abstainers as the reference category. For tests of
linear trend, we treated the categories of alcohol intake as the
continuous variable. For tests of quadratic trend, we squared the
linear trend variable. We included age, sex, and pack-years of
cigarette smoking as covariates. In addition, we adjusted for
educational level, BMI, diabetes, and hypertension. We evalu-
ated whether the effects of alcohol differed by sex or APOE
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genotype (carrier or noncarrier of the APOE 4 allele) by per-
forming stratified analyses and including interaction terms in the
model. Statistical analyses were performed by using SPSS
statistical software for WINDOWS (version 11.5; SPSS Inc,
Chicago).
RESULTS
There were no differences in baseline characteristics between
the total sample and the subsample in which hippocampal and
amygdalar volumes on MRI were evaluated (Table 1). Charac-
teristics according to alcohol intake categories are given for the
total sample in Table 2. Former drinkers (n  86 in the total
sample and n  42 in the subsample) had hypertension and
diabetes mellitus more frequently than did the current drinkers,
which supports our presumption that former drinkers might have
stopped drinking because of illness. Therefore, former drinkers
were excluded from analyses of alcohol intake and brain MRI
findings.
Light alcohol drinkers had the smallest amount of periven-
tricular white matter lesions on MRI [adjusted difference from
abstainers: 0.69 (95% CI: 0.25, 1.13; P  0.002); adjusted dif-
ference from heavy drinkers: 0.79 (95% CI: 0.17, 1.41; P 
0.01)], as shown in Table 3. The light alcohol drinkers also
tended to have fewer subcortical white matter lesions than did the
heavy drinkers, but the difference did not reach significance
[adjusted difference from abstainers: 0.57 (95% CI:0.05, 1.20;
P  0.07); adjusted difference from heavy drinkers: 0.35 (95%
CI:0.54, 1.24; P 0.44)]. Brain infarcts on MRI tended to be
found less frequently in very light and light drinkers, but none of
the odds ratios reached statistical significance (Table 3). When
we excluded persons with symptomatic infarcts on MRI (n 
42)—because they could have changed their alcohol intake after
the stroke—the results remained similar. The associations did
not change after additional adjustments for educational level,
BMI, diabetes, and hypertension, and they were similar in men
and women and in APOE 4 carriers and noncarriers.
Overall, there was no association between alcohol intake and
hippocampal or amygdalar volumes on MRI, as shown in Table
4. However, the effect of alcohol intake on volumes differed by
APOE genotype (P for interaction 0.02 for hippocampal vol-
ume and  0.07 for amygdalar volume). In carriers of the 4
allele, alcohol intake was positively associated with hippocam-
pal and amygdalar volumes, whereas, in 4 noncarriers, there
was no association (Figure 1). The associations between al-
cohol intake and hippocampal or amygdalar volumes did not
change after additional adjustment for educational level, BMI,
diabetes, and hypertension, and they were similar in men and
women.
In the total sample, there were 111 persons who fulfilled the
criteria for binge drinking (6 alcoholic drinks in1 d). Of this
group, 56 were also in the subset with hippocampal and amyg-
dalar data, and excluding them did not change the results.
TABLE 1
Characteristics of the total study sample and of the subsample with
assessment of hippocampal and amygdalar volumes on 3-dimensional
(3-D) magnetic resonance imaging (MRI)
Total sample
(n 1074)
Subsample with
3-D MRI
(n 509)
Age (y) 72 71 73 8
Women (%) 52 49
Current alcohol intake (drinks/d) 1.2 1.3 1.2 1.4
Former alcohol users (%) 8 8
Pack-years of cigarette smoking (y) 19 24 20 25
Primary education (%) 35 31
BMI (kg/m2) 27 4 26 4
Presence of diabetes (%) 7 6
Presence of hypertension (%) 52 53
Presence of APOE 4 allele (%)2 28 27
Presence of symptomatic infarct on
MRI (%)
4 6
1 x  SD (all such values). No significant differences were observed
between the samples.
2 Available in 969 out of the total sample and in 436 out of the sub-
sample.
TABLE 2
Characteristics according to current alcohol intake in the total sample1
Alcohol intake
P2
None
(n 114)
Very light
(1 drink/wk)
(n 195)
Light
(1 drink/wk
to1 drink/d)
(n 247)
Moderate
(1 drink/d to
4 drinks/d)
(n 386)
Heavy
(4 drinks/d)
(n 46)
Former
consumption
(n 86)
Age (y) 72 83 73 8 72 8 72 7 70 7 74 7 0.09
Women (%) 78 69 50 38 26 55 0.001
Pack-years of cigarette smoking (y) 7 16 14 22 18 22 23 24 37 33 21 25 0.001
Primary education (%) 45 38 34 28 39 45 0.003
BMI (kg/m2) 27 4 27 4 27 4 26 3 26 3 26 4 0.20
Presence of diabetes (%) 10 7 5 5 4 17 0.001
Presence of hypertension (%) 56 56 51 47 54 59 0.18
Presence of APOE 4 allele (%) 31 23 23 28 30 39 0.10
Presence of symptomatic infarct on
MRI (%)
6 3 2 5 4 2 0.42
1 MRI, magnetic resonance imaging.
2 ANOVA (continuous variables) or chi-square test (categorical variables).
3 x  SD (all such values).
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DISCUSSION
In this population-based study in older persons, we found that
drinkers of light-to-moderate amounts of alcohol had fewer ce-
rebral white matter lesions and brain infarcts on MRI than did
abstainers and heavy drinkers. In APOE 4 carriers, but not in 4
noncarriers, we found a positive association between alcohol
intake and hippocampal and amygdalar volumes on MRI.
Some aspects of the methods used in this study should be
discussed. First, there could be error in the MRI measures, par-
ticularly in the semiquantitative assessments. However, given
that MRI assessments were done with the investigators blinded to
the subjects’ alcohol intake, this is random error that only leads
to weaker associations between alcohol and MRI measures. Sec-
ond, we relied on self-reported alcohol intake, which may have
led to underreporting or overreporting. Although we may have
misclassified absolute amounts of alcohol intake, the ranking of
subjects according to their alcohol intake most likely was ade-
quate (32). If persons who actually drink heavily underreported
their alcohol consumption, we will have underestimated the dif-
ference in risk between those who drink moderately and abstain-
ers. Third, we assessed average alcohol intake over a 1-y period
before MRI examinations, but it might be better to have infor-
mation on the average alcohol intake over the lifetime. Moreover,
we lacked detailed information on drinking patterns, which may
be important in estimating the effects of alcohol. Fourth, we had
no information on the type of alcoholic drink consumed. Previ-
ous studies showed that beer, spirits, and wine—consumed in
moderation—are equally associated with a reduced risk of de-
mentia (2, 4), although the Copenhagen City Heart Study found
the association only for moderate wine consumption (10). Drink-
ing patterns in the older Dutch population studied here were
reported before (2); they show that, among alcohol consumers,
35% drink wine, 35% drink spirits, 30% drink fortified wine, and
20% drink beer. Finally, given that our study is observational and
that alcohol intake may be associated with several unmeasured
confounders, we cannot infer causality of the associations.
Light-to-moderate alcohol drinking is associated with a lower
risk of cognitive impairment and dementia than is lifetime ab-
stention (1–4, 10, 33, 34). In line with the beneficial effects of
alcohol on the lipid profile, hemostatic factors (6), and athero-
sclerosis (35), most investigators found a reduced risk of vascular
dementia in consumers of light-to-moderate amounts of alcohol
(2, 4, 5). We found that, consistent with these vascular effects of
alcohol and with observations in the Cardiovascular Health
Study (36), consumers of light-to-moderate amounts of alcohol
had fewer cerebral white matter lesions—in particular, those in
the periventricular region—and infarcts on MRI. Different
pathophysiologic events may lead to the development of either
periventricular or subcortical white matter lesions (14). The
periventricular white matter, in particular, is vulnerable to ische-
mia, and severe periventricular white matter lesions are related to
carotid atherosclerosis (37). The Atherosclerosis Risk in Com-
munities study of middle-aged subjects did not show an effect of
alcohol intake on cerebrovascular disease on MRI, but those
TABLE 3
Vascular brain magnetic resonance imaging (MRI) findings according to alcohol intake in the total sample
Alcohol intake P for trend
None
(n 114)
Very light
(1 drink/wk)
(n 195)
Light
(1 drink/wk to
1 drink/d)
(n 247)
Moderate
(1 drink/d to
4 drinks/d)
(n 386)
Heavy
(4 drinks/d)
(n 46) Linear Quadratic1
White matter lesions
Periventricular, grade2 2.73 0.193 2.51 0.14 2.04 0.12 2.37 0.10 2.83 0.29 0.001 0.001
Subcortical, volume (mL)2 1.58 0.27 1.60 0.20 1.01 0.18 1.49 0.14 1.36 0.42 0.31 0.36
Brain infarcts
[n (%)] 34 (30) 43 (22) 52 (21) 94 (24) 9 (20)
Odds ratio (95% CI)4 1.00 (reference) 0.63 (0.36, 1.09) 0.65 (0.38, 1.12) 0.86 (0.52, 1.43) 0.80 (0.33, 1.96) 0.14 0.11
1 Calculated from multiple linear regression models with alcohol intake in categories and its squared term.
2 Adjusted for age, sex, and pack-years of cigarette smoking; analysis of covariance was used for calculating adjusted means in groups.
3 x  SE (all such values).
4 Adjusted for age, sex, and pack-years of cigarette smoking; logistic regression was used to calculate adjusted odds ratios.
TABLE 4
Hippocampal and amygdalar volume on magnetic resonance imaging (MRI) according to alcohol intake in the subsample1
Alcohol intake P for trend
None
(n 38)
Very light
(1 drink/wk)
(n 97)
Light
(1 drink/wk
to1 drink/d)
(n 103)
Moderate
(1 drink/d to
4 drinks/d)
(n 209)
Heavy
(4 drinks/d)
(n 20) Linear Quadratic2
Hippocampal volume (mL)3 6.33 0.14 6.41 0.09 6.47 0.08 6.38 0.06 6.28 0.20 0.30 0.25
Amygdalar volume (mL)3 4.56 0.11 4.49 0.07 4.63 0.07 4.62 0.05 4.62 0.16 0.66 0.90
1 All values are x  SE.
2 Calculated from multiple linear regression models with alcohol intake in categories and its squared term.
3 Adjusted for age, sex, and pack-years of cigarette smoking; analysis of covariance was used for calculating adjusted means in groups.
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investigators combined moderate and heavy alcohol intake into
one category, which may have diluted any beneficial effect (38).
Light-to-moderate alcohol drinking has also been associated
with a reduced risk of Alzheimer disease in several (1, 3, 4, 10,
39), but not all (40, 41) studies. Besides reducing cerebrovascular
disease that contributes to the development of symptoms of Alz-
heimer disease (8, 9, 25), alcohol in moderate amounts may also
increase the release of acetylcholine of the hippocampus (11) and
induce the release of potentially beneficial prostaglandins (12).
In traditional Alzheimer disease, amyloid plaques and neurofi-
brillary tangles accumulate in the brain, with a high predilection
for the medial temporal lobe (42). This may lead to neuronal loss
and atrophy in vivo that are detectable on MRI even in persons
who have not yet developed clinical symptoms of dementia (17–
22). APOE 4 carriers are at increased risk of Alzheimer disease-
related neurologic disorders (43), atrophy of structures in the
medial temporal lobe (44), and clinical Alzheimer disease (13).
Observations in the Rotterdam Study suggested that light-to-
moderate alcohol consumption is associated with a reduced risk
of Alzheimer disease only in APOE 4 carriers (2). Carmelli et al
(45) also reported a stronger association of light drinking and
better cognitive performance in APOE 4 carriers than in non-
carriers. In the current study, we found that APOE 4 carriers who
were consumers of light-to-moderate amounts of alcohol had less
hippocampal and amygdalar atrophy than did abstainers. Al-
though not all persons with hippocampal or amygdalar atrophy
will develop Alzheimer disease, such persons are at increased
risk of clinical symptoms of Alzheimer disease (18), and, thus,
our findings support the hypothesis that there could be a reduced
risk of Alzheimer disease for consumers of light-to-moderate
amounts of alcohol who have the APOE 4 allele. It is currently
unclear which biological mechanisms could be involved in the
associations between alcohol and Alzheimer disease. We spec-
ulate that a putative antioxidative effect of alcohol (46) might
suppress the highly sensitive peroxidation of APOE 4 (47) and
thereby reduce amyloid plaque formation in the medial temporal
lobe (48, 49) or neurotoxicity of the -amyloid (50). Unlike the
current study, the Cardiovascular Health Study found a lower
risk of dementia in alcohol consumers to be more consistent
among persons without the APOE 4 allele (4). It is possible that
the youth of the population studied in the Rotterdam Study com-
pared with the age of the Cardiovascular Health Study population
led to these discrepancies, because the APOE 4 allele is a stron-
ger risk factor for Alzheimer disease at younger ages (13). The
Epidemiology of Vascular Aging study also found a reduced risk
of cognitive deterioration with alcohol intake in 4 noncarriers,
but, in that study, the APOE 4 allele itself was not a risk factor
for cognitive decline (51).
In conclusion, our findings suggest that light-to-moderate al-
cohol intake is associated with brain MRI findings that are related
to cerebrovascular disease and—in APOE 4 carriers—with hip-
pocampal and amygdalar atrophy on MRI. These findings are in
line with recent observations that light-to-moderate alcohol con-
sumption is associated with a reduced risk of dementia.
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